Tag: 100-200

On October 5, 2018, Park, Hojoon; Chekshin, Nikita; Shen, Peng-Xiang; Yu, Jin-Quan published an article.Safety of Pyridine-3-sulfonic acid The title of the article was Ligand-Enabled, Palladium-Catalyzed β-C(sp3)-H Arylation of Weinreb Amides. And the article contained the following:

Authors report the development of Pd(II)-catalyzed C(sp3)-H arylation of Weinreb amides. Both the inductive effect and the potential bidentate coordination mode of the Weinreb amides pose a unique challenge for this reaction development. A pyridinesulfonic acid ligand is designed to accommodate the weak, neutral-coordinating property of Weinreb amides by preserving the cationic character of Pd center through zwitterionic assembly of Pd/ligand complexes. D. functional theory (DFT) studies of the C-H cleavage step indicate that the superior reactivity of 3-pyridinesulfonic acid ligand, compared to Ac-Gly-OH and ligandless conditions, originates from the stabilization of overall substrate-bound Pd species. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Safety of Pyridine-3-sulfonic acid

The Article related to ligand palladium catalyzed beta carbon hydrogen arylation weinreb amide, crystal mol structure methyl fluorobenzyl methoxymethylcarbamoylcyclopropyl benzoate, mol structure calculation palladium weinreb amide complex intermediate, c(sp3)–h activation, ligand design, palladium, pyridinesulfonic acid, weinreb amide and other aspects.Safety of Pyridine-3-sulfonic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 29, 2021, Rai, Roopa; Booth, Robert; Green, Michael J. published a patent.Name: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Preparation of substituted (aza)benzimidazole-, indole-, quinolinecarboxamides and analogs as PGDH inhibitors. And the patent contained the following:

The title compounds I [X = OCH2, C(O)NH, NHC(O), etc.; each Y = (independently) N and substituted CH; each R1 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; R2 = H and R3 = CF3; or R2 and R3 are taken together to form oxo or thio; each R4 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; each R5 = (independently) halo, (halo)alkyl, cycloalkyl, etc.; n = 0-5; m = 0-4; and p = 0-10; with the proviso] or pharmaceutically acceptable salts thereof that can inhibit 15-hydroxyprostaglandin dehydrogenase, were prepared E.g., a multi-step synthesis of II, starting from 4-fluoro-3-nitrobenzoic acid, was described. Exemplified compounds I were evaluated in the hPGDH inhibitor screening biochem. assay (data given for representative compounds I). Compounds I may be administered to subjects that may benefit from modulation of prostaglandin levels. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Name: 6-(tert-Butyl)pyridin-3-amine

The Article related to benzimidazole azabenzimidazole indole quinoline carboxamide preparation pgdh inhibitor, prostaglandin level modulator benzimidazole azabenzimidazole indole quinoline carboxamide preparation, hydroxyprostaglandin dehydrogenase inhibitor benzimidazole azabenzimidazole indole quinoline carboxamide preparation and other aspects.Name: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 21, 1994, Schmuelling, Michael; Ryabov, Alexander D.; van Eldik, Rudi published an article.COA of Formula: C5H5NO3S The title of the article was To what extent can the Pt-C bond of a metallacycle labilize the trans position? A temperature- and pressure-dependent mechanistic study. And the article contained the following:

The orthoplatinated complexes [Pt{C6H3X(CH2NMe2)}(NC5H4SO3-3)(H2O)] (X = H 1a or 3-MeO 1b) were designed for mechanistic studies in H2O. The aqua ligand is located trans to the Pt-C bond of the Ph group which lies in the Pt(II) coordination plane. The rates of substitution of the aqua ligand by nucleophiles (Nu) (Cl-, Br-, I-, N3-, SCN-, thiourea, N,N’-dimethylthiourea or N,N,N’,N’-tetramethylthiourea) were studied as a function of concentration, pH, temperature, and pressure by using a stopped-flow technique. The pKa value of the aqua ligand in 1a is 9.75 ± 0.505 and the observed pseudo-first-order rate constants for the substitution reaction are given by kobs = k1[Nu] + k-1. The k-1 term arises from the reverse solvolysis reaction and is insignificant for stronger, S-donor nucleophiles. The values of k1 are ∼4 orders of magnitude higher than the corresponding rate constants for anation reactions of [Pt(dien)(H2O)]2+ (dien = diethylenetriamine) and close to the rate constants for anation of [Pd(dien)(H2O)]2+. The effect is largely due to a strong decrease in ΔH⧧, ΔS⧧ and ΔV⧧, clearly shows that the substantial rate increase is not associated with a changeover in mechanism and that the substitution process is still associative. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).COA of Formula: C5H5NO3S

The Article related to substitution kinetics nucleophile aminomethylplatinum complex, platinum aminomethyl substitution kinetics nucleophile, reactivity aminomethylplatinum complex nucleophile, reaction mechanism aminomethylplatinum complex nucleophile substitution, bond platinum carbon lability aminomethylplatinum metallacycle and other aspects.COA of Formula: C5H5NO3S

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 20, 2010, Soll, Mark David; Le Hir De Fallois, Loiec Patrick; Huber, Scot Kevin; Lee, Hyoung Ik; Wilkinson, Douglas Edward; Jacobs, Robert Toms; Beck, Brent Christopher published a patent.Synthetic Route of 1086838-13-2 The title of the patent was Preparation of enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds. And the patent contained the following:

The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula I (wherein P is C-R1 or N; Q is C-R2 or N; V is C-R8 or N; W is C-R9 or N; X is C-R10 or N; Y is C-R11 or N; R1, R2 R8, R9, R10 and R11 are independently H, NH2, amido, etc.; R3, R4 and R5 are independently H, halo, alkyl, etc., or R4 and R5 form part of a cycloalkyl ring; R6 is H, alkyl, alkoxyalkyl, etc. ; R7 is H, alkyl, cycloalkyl, etc.; Z is a direct bond, C(O), C(S) or S(O)p; a = 1-3; p = 0-2), compositions thereof, processes for their preparation, and their uses as pesticides, in particular for controlling endo- and ectoparasites that are harmful to mammals, fish and birds. Example compound II, prepared by reacting 4-trifluoromethoxybenzoyl chloride and (R)-2-amino-3-(6-bromopyrazolo[4,3-b]pyridin-2-yl)-2-methylpropionitrile (preparation given), showed 100% efficacy against ivermectin-resistant endoparasites at an oral dose of 1.5 mg/kg in sheep. The experimental process involved the reaction of 5-Chloro-3-nitropicolinaldehyde(cas: 1086838-13-2).Synthetic Route of 1086838-13-2

The Article related to enantiomerically enriched aryloazolyl cyanoethylamino parasiticide preparation, benzotriazole cyanoethylamino preparation antiparasitic endoparasite ectoparasite, indazole cyanoethylamino preparation parasiticidal infection, endoparasite ectoparasite pesticidal pyrazolopyridine cyanoethylamino preparation and other aspects.Synthetic Route of 1086838-13-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 5, 2014, Walsh, Shawn P.; Cato, Brian; Frie, Jessica L.; Kim, Dooseop; Pasternak, Alexander; Shi, Zhi-Cai published a patent.Recommanded Product: 868551-99-9 The title of the patent was Preparation of piperidine derivatives as inhibitors of the renal outer medullary potassium channel for treating cardiovascular diseases and edematous conditions. And the patent contained the following:

The present invention provides compounds of Formula I (wherein n = 0-1; the N-containing ring system is (un)substituted piperidinyl, etc.; R1 is -H, -OC1-3alkyl or -OH; R2 is -H or C1-3alkyl; R3 is -H, -F, -C1-3 alkyl or phenyl; or when n is 0, R2 and R3 are joined together to form a 4-6 member ring with the nitrogen and carbon to which each is attached; R4 and R5 are each independently -H or -C1-3-alkyl, or R4 and R5 are joined together with the carbon to which they are attached to form C3-6 cycloalkyl; Z1 is (un)substituted Ph, (un)substituted benzofuranyl, or (un)substituted benzopyranyl, and Z2 is a substituted N-containing heterocyclyl, (un)substituted Ph, etc.), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting intermediates 1-oxo-N-(piperidin-4-yl)-1,3-dihydroisobenzofuran-5-carboxamide hydrochloride and (4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)acetaldehyde. In the ROMK channel functional thallium flux assay, II had an IC50 of 0.01 μM. The experimental process involved the reaction of Methyl 5-amino-4-methylpicolinate(cas: 868551-99-9).Recommanded Product: 868551-99-9

The Article related to preparation piperidine derivative inhibitor renal medullary potassium channel, cardiovascular disease piperidine derivative inhibitor renal medullary potassium channel, edema treatment piperidine derivative inhibitor renal medullary potassium channel and other aspects.Recommanded Product: 868551-99-9

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 21, 2006, van Herrikhuyzen, Jeroen; Jonkheijm, Pascal; Schenning, Albertus P. H. J.; Meijer, E. W. published an article.Quality Control of [2,2′-Bipyridine]-3,3′-diamine The title of the article was The influence of hydrogen bonding and π-π stacking interactions on the self-assembly properties of C3-symmetrical oligo(p-phenylenevinylene) discs. And the article contained the following:

Three nonracemic C3-sym. oligophenylenevinylenes (OPV) are prepared and characterized; the UV/visible and IR spectra of the products in solution are determined and used to characterize the structures formed by self-assembly of the OPV. OPVs with triaminobenzene and benzenetricarboxamide cores show two-step transitions from helical stacks to molecularly dissolved species; the orientation of the amide relative to the core determines the stabilities and helicities of fibers in solution and the lengths of fibrils formed at surfaces. An OPV with a tris(2,2′-bipyridin-3-yl)benzenetricarboxamide core forms aggregates that show little chiral ordering but which remain present over a large temperature range; at surfaces, completely disordered structures exist as a result of competing types of π-π stacking interactions that differ in strength and orientation. The design of functional self-assembled architectures based on hydrogen bonding and π-π stacking interactions requires careful balancing of the topologies, directionalities and strengths of secondary interactions. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Quality Control of [2,2′-Bipyridine]-3,3′-diamine

The Article related to oligophenylenevinylene nonracemic preparation uv visible spectra self assembly, aggregation pi stacking hydrogen bonding interaction nonracemic oligophenylenevinylene, hydrogen bonding pi interaction self assembly sym oligophenylenevinylene disk and other aspects.Quality Control of [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 29, 1992, Alo, Babajide I.; Familoni, Oluwole B.; Marsais, Francis; Queguiner, Guy published an article.Safety of Pyridine-3-sulfonic acid The title of the article was Directed metalation of pyridinesulfonamides. Synthesis of pyridine-fused isothiazoles and 1,2-oxathioles. And the article contained the following:

4-Lithio-N-tert-butylpyridine-3-sulfonamide reacted with Ph2CO or CO2 to give the corresponding intermediates, which on appropriate treatment gave the addition product I (from Ph2CO reaction product) or isothiazolo[5,4-c]pyridin-3-one 1,1-dioxides II (R = H, Me3C) (from CO2 reaction product). Metalation of 2- and 4-[N,N-(dialkylamino)sulfonyl]pyridines with LiN(CHMe2)2 gave anions which reacted with Ph2CO to give carbinols, which cyclized thermally to 1,2-oxathiolo[3,4-b]- III and -[4,3-c]pyridine dioxide IV, resp. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Safety of Pyridine-3-sulfonic acid

The Article related to sultone pyridine fused, sultam pyridine fused, pyridinesulfonamide directed lithiation, isothiazolopyridinone dioxide, oxathiolopyridine, aminosulfonylpyridine lithiated reaction benzophenone, intramol cyclocondensation sulfonylpyridylmethanol and other aspects.Safety of Pyridine-3-sulfonic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On July 21, 2005, Kelly, Michael G.; Janagani, Satyanarayana; Wu, Guoxian; Kincaid, John; Lonergan, David; Fang, Yunfeng; Wei, Zhi-Liang published a patent.Related Products of 39919-70-5 The title of the patent was Preparation of bicycloheteroarylamines like 2,6-naphthyridinamines and pyrido[3,4-d]pyrimidinamine as ion channel ligands and uses thereof. And the patent contained the following:

Amine compounds (shown as I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; and stereoisomers and tautomers thereof; variables defined below; e.g. 7-(3-chloropyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine (shown as II)) that are VR1 (VR = vanilloid receptor) antagonists are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of nonlimiting example, pain, inflammation, traumatic injury, and others. Compounds I are considered to be particularly beneficial as VR1 antagonists as certain compounds exhibit improved aqueous solubility and metabolic stability. For I: A and B = CH2, CR2’R2′, CO, CS and NR2′; Y = CH2, CR2’R2′ and NR2′; W and Z = CR4 and N, provided that W and Z both can not be N; R1 = (un)substituted aliphatic, alkyl, heteroalkyl, acyl, aryl, heteroaryl, aralkyl, heteroalkyl; each of R2 and R2′ = H, or (un)substituted C1-C6 alkyl, C1-C6 cycloalkyl, aryl and aralkyl; R3 = (un)substituted C1-C6 alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, bicycloalkyl, bicycloheteroalkyl, bicycloalkenyl, bicycloheteroalkenyl, bicycloaryl, and bicycloheteroaryl ring. R4 = H, or (un)substituted alkyl, (un)substituted acyl, (un)substituted acylamino, (un)substituted alkylamino, (un)substituted alkylthio, (un)substituted alkoxy, (un)substituted alkoxycarbonyl, (un)substituted alkylarylamino, (un)substituted arylalkyloxy, amino, (un)substituted aryl, arylalkyl, (un)substituted sulfoxide, (un)substituted sulfone, (un)substituted mercapto, (un)substituted aminosulfonyl, (un)substituted arylsulfonyl, sulfuric acid, sulfuric acid ester, (un)substituted dihydroxyphosphoryl, (un)substituted aminodihydroxyphosphoryl, azido, carboxy, (un)substituted carbamoyl, carboxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloheteroalkyl, (un)substituted dialkylamino, halo, heteroaryloxy, (un)substituted heteroaryl, (un)substituted heteroalkyl, hydroxy, nitro, and thio. Although the methods of preparation are not claimed, 62 example preparations are included. For example, II was prepared in 5 steps (90, 38, 91, 87, 26 % yields) starting from 1-benzyl-3-(ethoxycarbonyl)-4-piperidone hydrochloride, formamidine acetate and NaOMe/MeOH and involving intermediates 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one, 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 7-benzyl-N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine, and N-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-amine. VR1 antagonist activity for 62 examples of I, capsaicin-induced VR1 current inhibition activity for 16 examples of I, reversal of thermal hyperalgesia in rats by II, pharmacokinetic profiles for 5 examples of I and plasma protein binding ability by II are reported. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Related Products of 39919-70-5

The Article related to naphthyridinamine pyridopyrimidinamine preparation vanilloid receptor antagonist, ion channel ligand naphthyridinamine pyridopyrimidinamine preparation, pain inflammation traumatic injury drug naphthyridinamine pyridopyrimidinamine preparation and other aspects.Related Products of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 15, 2007, Wang, Jian; Djukic, Brandon; Cao, Jingyi; Alberola, Antonio; Razavi, Fereidoon S.; Pilkington, Melanie published an article.HPLC of Formula: 75449-26-2 The title of the article was A novel bis tridentate bipyridine carboxamide ligand and its complexation to copper(II): synthesis, structure, and magnetism. And the article contained the following:

A new bis tridentate ligand 2,2′-bipyridine-3,3′-[2-pyridinecarboxamide] H2L1 which can bind transition metal ions was synthesized via the condensation of 3,3′-diamino-2,2′-bipyridine together with 2-pyridine carbonyl chloride. Two Cu(II) coordination compounds were prepared and characterized: [Cu2(L1)(hfac)2].3MeCN.H2O (1) and [Cu2(L1)Cl2].MeCN (2). The single-crystal x-ray structures reveal that complex 1 crystallizes in the triclinic space group P1̅, with a 12.7185(6), b 17.3792(9), c 19.4696(8) Å, α 110.827(2), β 99.890(3), γ 97.966(3)°, Z = 4, R = 0.0321 and Rw = 0.0826. Complex 2 crystallizes in the monoclinic space group P21/n with a 12.8622(12), b 9.6100(10), c 19.897(2) Å, β 102.027(3)°, Z = 4, R = 0.0409 and Rw = 0.1005. In both complexes the ligand is in the dianionic form and coordinates the divalent CuII ions via one amido and two pyridine N donor atoms. In 1, the coordination geometry around both CuII ions is best described as distorted trigonal bipyramidal where the remaining two coordination sites are satisfied by hexafluoroacetylacetonate counterions. In 2 both CuII ions adopt a (4 + 1) distorted square pyramidal geometry. One Cu forms a longer apical bond to an adjacent carbonyl O atom, whereas the second Cu is chelated to a neighboring Cu-Cl chloride ion to afford a μ-Cl-bridged dimerized [Cu2(L1)Cl2]2 complex. The magnetic susceptibility data for 1 (2 -270 K), reveal the occurrence of weak antiferromagnetic interactions between the CuII ions. In contrast, variable-temperature magnetic susceptibility measurements for 2 reveal more complex magnetic properties, with the presence of a weak antiferromagnetic exchange (J = -10.1 K) between the Cu ions in each dinuclear Cu complex and a stronger ferromagnetic exchange interaction (J = 32.9 K) between the CuII ions of the Cu(μ-Cl)2Cu dimeric bridging units. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).HPLC of Formula: 75449-26-2

The Article related to copper bipyridinepyridinecarboxamide preparation structure magnetic exchange, crystal structure copper bipyridinepyridinecarboxamide fluoroacac chloro dinuclear, exchange ferromagnetic antiferromagnetic copper bipyridinepyridinecarboxamide and other aspects.HPLC of Formula: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 18, 2014, Hurley, Nicholas J.; Hayward, John J.; Rawson, Jeremy M.; Murrie, Mark; Pilkington, Melanie published an article.SDS of cas: 75449-26-2 The title of the article was Exploring the Coordination Chemistry of 3,3′-Di(picolinamoyl)-2,2′-bipyridine: One Ligand, Multiple Nuclearities. And the article contained the following:

The syntheses, structures, and magnetic properties of three new coordination complexes, tetranuclear [Zn2L3(OAc)(OMe)]2·3MeOH·H2O (3), trinuclear [Ni3(L3)3]·6H2O (4), and a 1-dimensional chain {[Cu2L3(OAc)2]2·H2O}n (6), of a polydentate, doubly deprotonated, disubstituted bipyridine ligand, 3,3′-bis(picolinamido)-2,2′-bipyridine, [L3]2-, are reported. The x-ray crystal structures demonstrate that the ditopic ligand provides a flexible N3 donor set for transition metal ions where each binding pocket shifts from fac to intermediate fac/mer to the mer isomer affording a Ni3 triangle, a Zn4 tetramer, and a 1-dimensional Cu(II) polymer, resp. This variation in coordination preference is rationalized with the aim of designing future ligands with controlled coordination modes. Magnetic susceptibility studies on 4 reveal it belongs to the rare family of ferromagnetically coupled [Ni3] clusters. In contrast, magnetic studies of the 1-dimensional chain 6 reveal weak antiferromagnetic interactions due to the poor orbital overlap of the singly occupied Cu(II) dx2-y2 orbitals with the 1-atom bridge that connects them along the Jahn-Teller distortion axis. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).SDS of cas: 75449-26-2

The Article related to transition metal bispicolinamidobipyridine multinuclear complex coordination polymer preparation, crystal structure transition metal bispicolinamidobipyridine multinuclear complex coordination polymer, magnetic property transition metal bispicolinamidobipyridine multinuclear complex coordination polymer and other aspects.SDS of cas: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem